BIO-PATH HOLDINGS INC (BPTH)
US09057N4097 - Common Stock
Which stocks are experiencing notable movement on Monday?
Top movers in Monday's session
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its...
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its...
Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
Walgreens layoffs are in the news Thursday after the pharmacy chain announced plans to cut jobs in Chicago while reducing employees' hours.
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe stock is rallying on Wednesday after the company's CEO announced plans to take ME shares private in a potential deal.
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform...
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET...
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize®...
Bio-Path announces 1-for-20 reverse stock split, effective Feb 22 (NASDAQ:BPTH)
Bio-Path Holdings announces a 1-for-20 reverse stock split, effective Feb 22, 2024.
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024...
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
Bio-Path files to sell shares (NASDAQ:BPTH)
Bio-Path files prospectus for public offering of shares and warrants, but it is not an offer to sell securities.
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 Protein...